Archives

More patients receiving asciminib than investigator-selected tyrosine kinase inhibitor had major molecular response at 48 weeks

Crinecerfont results in greater decrease from baseline in mean daily glucocorticoid dose among patients with CAH

Fewer palliative care visits seen with stepped-care model, but noninferiority seen in the Functional Assessment of Cancer Therapy-Lung score

Authors found that BMI of ≥27 shows excellent diagnostic performance

Reduction seen in risk for clinically important kidney outcomes and death from cardiovascular causes

Those receiving pulmonologist-directed treatment have less subsequent health care utilization for respiratory illness

Similarly accurate prediction seen for respiratory outcomes, but occupational eligibility and disability compensation differed

Increase seen in prebronchodilator forced expiratory volume in one second with dupilumab versus placebo at weeks 12, 52

Second study shows cardiovascular benefit for semaglutide, regardless of weight loss

Survival benefits disappear when only high-quality studies are pooled and with adjustment for potential publication bias